We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
101
DELISTED
Day One Biopharmaceuticals
DAWN
$484K 0.09%
+35,100
New +$514K
GOSS icon
102
Gossamer Bio
GOSS
$88.7M
$480K 0.09%
532,628
-200,000
-27% -$150K
ABEO icon
103
Abeona Therapeutics
ABEO
$389M
$480K 0.09%
+113,125
New +$577K
ALNY icon
104
Alnylam Pharmaceuticals
ALNY
$29.3B
$450K 0.08%
1,850
-178,295
-99% -$28.1M
PYPD icon
105
PolyPid
PYPD
$85.3M
$447K 0.08%
+103,950
New +$465K
SNY icon
106
Sanofi
SNY
$102B
$442K 0.08%
9,100
+3,600
+65% +$174K
TXMD icon
107
TherapeuticsMD
TXMD
$23.6M
$435K 0.08%
270,160
-2,000
-0.7% -$4.04K
JBIO
108
Jade Biosciences
JBIO
$1.3B
$410K 0.08%
7,055
+6,601
+1,454% +$4.38M
CGON icon
109
CG Oncology
CGON
$6.3B
$406K 0.08%
12,850
+10,800
+527% +$374K
RNXT icon
110
RenovoRx
RNXT
$46.9M
$401K 0.08%
+355,240
New +$436K
TRIP icon
111
TripAdvisor
TRIP
$1.67B
$392K 0.07%
+22,000
New +$477K
MOVE icon
112
Corvex Inc
MOVE
$379M
$387K 0.07%
+12,738
New +$611K
WVE icon
113
Wave Life Sciences
WVE
$1.18B
$382K 0.07%
76,651
+46,651
+156% +$266K
GERN icon
114
Geron
GERN
$860M
$382K 0.07%
90,000
+88,705
+6,850% +$346K
ZLAB icon
115
Zai Lab
ZLAB
$2.09B
$381K 0.07%
22,000
– –
ABVX
116
Abivax
ABVX
$10.9B
$357K 0.07%
27,000
+12,000
+80% +$172K
ABT icon
117
Abbott
ABT
$182B
$343K 0.06%
3,300
+1,900
+136% +$201K
YARW
118
Yarrow Bioscience, Inc. Common Stock
YARW
$25.3M
$337K 0.06%
3,424
+1,222
+55% +$152K
OPCH icon
119
Option Care Health
OPCH
$3.55B
$332K 0.06%
12,000
+5,000
+71% +$149K
JANX icon
120
Janux Therapeutics
JANX
$973M
$331K 0.06%
7,891
-6,109
-44% -$287K
GRAL
121
GRAIL Inc
GRAL
$3.12B
$329K 0.06%
+21,401
New +$347K
OAKU
122
DELISTED
Oak Woods Acquisition Corp
OAKU
$326K 0.06%
30,000
– –
ORKA
123
Oruka Therapeutics
ORKA
$5.92B
$324K 0.06%
+7,056
New +$281K
JVSAU
124
DELISTED
JVSPAC Acquisition Corp. Unit
JVSAU
$313K 0.06%
30,000
– –
MLYS icon
125
Mineralys Therapeutics
MLYS
$2.34B
$297K 0.06%
25,366
+1,366
+6% +$17.2K
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.